Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ezetimibe + rosuvastatin calcium
- Development stage
- Unknown
- Lead developer
- Hanmi Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ezetimibe + rosuvastatin calcium is a fixed-dose combination (FDC) oral therapy consisting of ezetimibe, a selective cholesterol absorption inhibitor, and rosuvastatin calcium, an HMG-CoA reductase inhibitor (statin). Ezetimibe targets the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine to reduce dietary and biliary cholesterol absorption. Rosuvastatin inhibits the rate-limiting enzyme in hepatic cholesterol synthesis. This dual mechanism provides complementary lipid-lowering effects, primarily used for treating hypercholesterolemia and familial hypercholesterolemia. Beijing Hanmi Pharmaceutical is developing this FDC as a generic version of the branded product Rosuzet.
- Brand names
- Rosuzet
- Other names
- Ezetimibe Rosuvastatin Calcium Tables
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)NPC1L1 (Niemann-pick C1-Like 1 transporter)
Beyond the preview
Go deeper on ezetimibe + rosuvastatin calcium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ezetimibe + rosuvastatin calcium.